Clinical Edge Journal Scan

Breast-conserving surgery over mastectomy in early-stage adenoid cystic carcinoma of the breast


 

Key clinical point: Breast-conserving surgery (BCS) led to similar overall survival (OS) and better disease-specific survival (DSS) outcomes compared with mastectomy in patients with stage I/II adenoid cystic carcinoma of the breast (BACC).

Major finding: The 10-year OS rates were comparable between the BCS and mastectomy groups ( P = .968), whereas DSS was significantly improved in patients who underwent BCS vs mastectomy (95% vs 89%; P = .002).

Study details: Findings are from an analysis of the Surveillance, Epidemiology, and End Results Program (SEER) including 583 patients with stage I/II BACC, of whom 386 patients underwent BCS and 197 patients underwent mastectomy.

Disclosures: This study was supported by various grants from the Science and Technology Department of Henan Province, China. The authors declared no conflicts of interest.

Source: Huang T et al. Optimal surgical procedure for treating early-stage adenoid cystic carcinoma of the breast. Sci Rep. 2023;13:10222 (Jun 23). Doi: 10.1038/s41598-023-36644-w

Recommended Reading

Higher risk of death with endocrine therapy nonadherence
Breast Cancer ICYMI
Fatigue after breast cancer radiotherapy: Who’s most at risk?
Breast Cancer ICYMI
Interrupting radiotherapy for TNBC linked to worse survival
Breast Cancer ICYMI
U.S. mammogram update sparks concern, reignites debates
Breast Cancer ICYMI
Meta-analysis establishes association between meningioma and breast cancer
Breast Cancer ICYMI
Interrupting treatment during adjuvant radiotherapy tied to worsened survival in TNBC
Breast Cancer ICYMI
Higher BMI has an indirect impact on prognosis in invasive lobular breast cancer
Breast Cancer ICYMI
Worse prognosis in invasive lobular carcinoma vs other special breast cancer types
Breast Cancer ICYMI
Immediate breast reconstruction after mastectomy can be a possibility in early breast cancer
Breast Cancer ICYMI
Adherence and longer persistence to adjuvant hormone therapy benefits older HR+ BC patients
Breast Cancer ICYMI